NuGene International Inc (OTCBB:NUGN) reported the addition of Jon’Ric International to its Elite Signature Salon Plan. The franchisor firm will commence actively promoting and offering NuGene’s products throughout its extensive worldwide network of dental, medical, wellness, and day spa salons and franchises.
Jon’Ric International is a thirty-two year-old leading franchisor of fashionable specialty salon and spa experiences within the U.S. and internationally. For more than three decades, the firm has been a worldwide leader in wellness and spa innovation and is famous for offering only the highest quality and latest products and state-of-the-art services through its franchises.
NuGene and Jon’Ric were brought on the same platform by Kathleen E. Morton, PA-C. It belongs to the list of the longest tenured franchisees with the group. The head of the Jon’Ric franchise in Edmond, said that being a healthcare professional and a medical spa owner, the firm’s patients relies on them to get the absolute best products in the market. Their firm found NuGene and felt delighted to share the remarkable results with their other franchisees. The entire team is thrilled to offer the best products worldwide.
The expert speak
Dr. John Rando, the CEO and founder of Jon’Ric International, said that the clients and patients expect the best from them. They search the international markets in order to provide the latest and state-of-the-art medical-grade products to clients. NuGene has appreciably advanced hair and skin care technology and Jon’Ric clients will benefit by using the most unique products on the market. Dr. Thomas Taylor, the Medical Director of Jon’Ric, was extremely impressed with company’s stem cell technology.
In last trading session, the stock price of NuGene declined more than 10% to close the trading session at $2.55. The decline came at a share volume of 371,277 compared to monthly average share volume of 335,985.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: